4TEEN4 Pharmaceuticals
Hennigsdorf
About 4TEEN4 Pharmaceuticals
4TEEN4 Pharmaceuticals GmbH is a biopharmaceutical company developing Procizumab, a first in class antibody therapy targeting circulating Dipeptidyl Peptidase 3 (cDPP3), a validated biotarget for the treatment of Circulatory Shock. 4TEEN4 Pharmaceuticals GmbH developed and out-licenses a DPP3 assay, for prediction and stratification of patients in danger of entering into Circulatory Shock
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $95.9M
- Funding stage: Late Stage Venture
- Last round: Series C (Nov 2025)
- Website: 4teen4.de
- Phone: +49 33 02/866 885-0
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Hospital, Medical
Social Profiles
Canonical: https://fsome.com/organization/4teen4-pharmaceuticals-6334 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.